Dediabetes Logo
Evidence Hub
Learn what works
Latest Research
Newest studies
What Changed
Weekly intelligence
Settings
Login / Sign up

SGLT2 Inhibitors for Diabetes: Evidence and Outcomes

Evidence on outcomes studied for SGLT2 Inhibitors

Evidence related to SGLT2 inhibitor therapies in diabetes studies.

18
Studies
90
Evidence Pairs
Limited Evidence
Evidence Strength: 44/100

Evidence summary for AI and search

Among 18 indexed studies and 4 interventions, the strongest signals are summarized from deterministic graph patterns. HbA1c appears to be one of the clearer current evidence signals.

  • Evidence is consistently positive across multiple studies.
  • Some evidence is positive, but results are not consistent across all studies.
  • Early findings are encouraging, but stronger trials are needed.

Dediabetes summarizes indexed research evidence for education and discovery. This content is not medical advice and should not replace guidance from a qualified clinician.

Supporting Studies

18

Research documents analyzed

Evidence Pairs

90

Intervention-outcome relationships

Latest Publication

Jun 2026
Powered by the Dediabetes Evidence Intelligence™ framework

Evidence Snapshot

Qualitative overview of the evidence landscape

Low Confidence

Based on 18 studies, emerging evidence suggests HbA1c, Renal and urinary disorders incidence, All-cause mortality are the strongest-supported outcomes for sglt2 inhibitors.

Evidence Intelligence™

Evidence Snapshot

A structured summary of where the evidence is strongest, mixed, or still emerging.

View all supporting studies

Evidence at a Glance

18
Studies
4
Interventions
79
Outcomes
0
Strong evidence signals
0
Mixed evidence areas
Evidence freshness
Jun 2026
Latest indexed
Evidence Story

SGLT2 Inhibitors evidence appears to center on HbA1c.

Among 18 indexed studies and 4 interventions, the strongest signals are summarized from deterministic graph patterns. HbA1c appears to be one of the clearer current evidence signals.

  • Evidence is consistently positive across multiple studies.
  • Some evidence is positive, but results are not consistent across all studies.
  • Early findings are encouraging, but stronger trials are needed.
Caution

This summary reflects the currently indexed evidence and should not be interpreted as treatment advice.

Freshness

Latest indexed evidence: June 2026

Key Finding

Evidence is consistently positive across multiple studies.

Interventions with strongest consistent evidence

Strongest consistent evidence

Why it matters

Consistent positive findings are easier to interpret than isolated or mixed results.

Interpretation

HbA1c appears to have a consistent beneficial signal in the indexed evidence.

View supporting studies
Evidence basis: 3 evidence pairs - 9 studies

Why this appears here

Moderate evidenceConsistent resultsPositive effect signalMultiple RCTs
HbA1c
9 studies
EvidenceScore™
60/100
ConsensusScore™
76/100

Supporting Evidence

Mixed or conflicting evidence

Some evidence is positive, but results are not consistent across all studies.

Areas where results are mixed

Why it matters

Mixed results suggest effects may depend on population, comparator, duration, or study design.

Interpretation

HbA1c is mixed in the currently indexed evidence.

Caution

Some supporting studies reported neutral, negative, or mixed findings.

Top entities

HbA1c
All-cause mortality
HbA1c
9 studies
EvidenceScore™
60/100
ConsensusScore™
76/100

Why this appears here

Mixed Or Conflicting ResultsPositive Signal PresentNeutral Results Present
Evidence basis: 11 evidence pairs - 15 studies
View supporting studies
Promising but understudied

Early findings are encouraging, but stronger trials are needed.

Promising areas needing more evidence

Why it matters

Promising signals can guide further review, but they should not be treated as settled evidence.

Interpretation

Renal and urinary disorders incidence may have a beneficial signal, but the evidence base is still developing.

Caution

Current support is limited by study volume, RCT depth, or evidence strength.

Top entities

Renal and urinary disorders incidence
All-cause mortality
Renal and urinary disorders incidence
2 studies
EvidenceScore™
60/100
ConsensusScore™
50/100

Why this appears here

Positive effect signalLimited study volumeFew randomized trialsEmerging Or Limited Strength
Evidence basis: 9 evidence pairs - 5 studies
View supporting studies

Practical Questions

Organized using the Dediabetes Evidence Intelligence™ framework.

What outcomes has SGLT2 Inhibitors been studied for?

outcomes studied
Emerging Evidence

HbA1c, Renal and urinary disorders incidence, and All-cause mortality are among the most studied areas in relation to SGLT2 Inhibitors.

ConsensusScore™: Consistency cannot yet be determined from the available evidence.

Evidence caveat: The evidence includes both beneficial and harmful or worsening results.

Ranked evidence signals

  1. 1

    HbA1c

    EvidenceScore™ Moderate | EvidenceScore™ 60.1 | moderate positive | ConsensusScore™ Consistent | 9 studies

  2. 2

    Renal and urinary disorders incidence

    EvidenceScore™ Emerging | EvidenceScore™ 60.0 | strong positive | ConsensusScore™ Unclear | 2 studies

  3. 3

    All-cause mortality

    EvidenceScore™ Emerging | EvidenceScore™ 56.7 | strong positive | ConsensusScore™ Unclear | 4 studies

Why this answer: This answer is cautious because the available studies report mixed findings.

Limitations

  • Consistency cannot yet be determined.

Applicability

Population details were available for 1 of 18 supporting studies: Participants were adults with type 2 diabetes and high cardiovascular risk recruited from a Shanghai tertiary hospital. Groups were generally balanced at baseline, although hypertension and some background medication....

18 supporting studies14 RCTs, 1 meta-analysisLatest publication: Jun 2026Updated: Jul 2026

Does SGLT2 Inhibitors improve HbA1c?

intervention outcome_effect
Moderate Evidence

SGLT2 Inhibitors may improve HbA1c.

ConsensusScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    HbA1c

    EvidenceScore™ Moderate | EvidenceScore™ 60.1 | moderate positive | ConsensusScore™ Consistent | 9 studies

Why this answer: This answer is based on 9 supporting studies with consistent results and a positive effect signal.

Applicability

Population details were available for 1 of 9 supporting studies: Participants were adults with type 2 diabetes and high cardiovascular risk recruited from a Shanghai tertiary hospital. Groups were generally balanced at baseline, although hypertension and some background medication....

9 supporting studies6 RCTs, 1 meta-analysisLatest publication: Jun 2026Updated: Jul 2026

Which outcomes have the strongest evidence for SGLT2 Inhibitors?

evidence strength
Emerging Evidence

HbA1c, Renal and urinary disorders incidence, and All-cause mortality have the strongest available evidence signals for SGLT2 Inhibitors.

ConsensusScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    HbA1c

    EvidenceScore™ Moderate | EvidenceScore™ 60.1 | moderate positive | ConsensusScore™ Consistent | 9 studies

  2. 2

    Renal and urinary disorders incidence

    EvidenceScore™ Emerging | EvidenceScore™ 60.0 | strong positive | ConsensusScore™ Unclear | 2 studies

  3. 3

    All-cause mortality

    EvidenceScore™ Emerging | EvidenceScore™ 56.7 | strong positive | ConsensusScore™ Unclear | 4 studies

Why this answer: This answer is based on 13 supporting studies and existing graph evidence signals.

Limitations

  • Consistency cannot yet be determined.

Applicability

Population details were available for 1 of 13 supporting studies: Participants were adults with type 2 diabetes and high cardiovascular risk recruited from a Shanghai tertiary hospital. Groups were generally balanced at baseline, although hypertension and some background medication....

13 supporting studies9 RCTs, 1 meta-analysisLatest publication: Jun 2026Updated: Jul 2026

Where does SGLT2 Inhibitors need more research?

research gaps
Emerging Evidence

Renal and urinary disorders incidence, All-cause mortality, and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization) need more research in relation to SGLT2 Inhibitors.

ConsensusScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Renal and urinary disorders incidence

    EvidenceScore™ Emerging | EvidenceScore™ 60.0 | strong positive | ConsensusScore™ Unclear | 2 studies

  2. 2

    All-cause mortality

    EvidenceScore™ Emerging | EvidenceScore™ 56.7 | strong positive | ConsensusScore™ Unclear | 4 studies

  3. 3

    Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

    EvidenceScore™ Emerging | EvidenceScore™ 56.7 | strong positive | ConsensusScore™ Unclear | 2 studies

Why this answer: This answer is based on 5 supporting studies and existing graph evidence signals.

Limitations

  • Consistency cannot yet be determined.
  • Population details are unavailable.
5 supporting studies3 RCTs, 1 meta-analysisLatest publication: May 2026Updated: Jul 2026

How does SGLT2 Inhibitors compare across studied outcomes?

cross outcome_comparison
Emerging Evidence

HbA1c, Renal and urinary disorders incidence, and All-cause mortality have available evidence for SGLT2 Inhibitors, but the comparison requires review of the underlying studies.

ConsensusScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    HbA1c

    EvidenceScore™ Moderate | EvidenceScore™ 60.1 | moderate positive | ConsensusScore™ Consistent | 9 studies

  2. 2

    Renal and urinary disorders incidence

    EvidenceScore™ Emerging | EvidenceScore™ 60.0 | strong positive | ConsensusScore™ Unclear | 2 studies

  3. 3

    All-cause mortality

    EvidenceScore™ Emerging | EvidenceScore™ 56.7 | strong positive | ConsensusScore™ Unclear | 4 studies

Why this answer: This answer is based on 13 supporting studies and existing graph evidence signals.

Limitations

  • Consistency cannot yet be determined.

Applicability

Population details were available for 1 of 13 supporting studies: Participants were adults with type 2 diabetes and high cardiovascular risk recruited from a Shanghai tertiary hospital. Groups were generally balanced at baseline, although hypertension and some background medication....

13 supporting studies9 RCTs, 1 meta-analysisLatest publication: Jun 2026Updated: Jul 2026

Top outcomes affected

Outcome areas reported in the evidence summary.

Rank #1

HbA1c

EvidenceScore™
60/100
ConsensusScore™
Consistent
Direction: moderate positive
Studies: 9
Rank #2

Renal and urinary disorders incidence

EvidenceScore™
60/100
ConsensusScore™
Unclear
Direction: strong positive
Studies: 2
Rank #3

All-cause mortality

EvidenceScore™
57/100
ConsensusScore™
Unclear
Direction: strong positive
Studies: 4

Strongest evidence relationships

Key patterns and insights identified across the research landscape

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

Moderate positive signal

HbA1c

Across 5 studies, Dapagliflozin shows a consistent moderate positive signal for HbA1c.

5 studies
EvidenceScore™: 60.1016129032258/100
View supporting studies
Strong positive signal

Renal and urinary disorders incidence

Across 1 study, Dapagliflozin shows a strong positive signal for Renal and urinary disorders incidence.

1 studies
EvidenceScore™: 59.95/100
View supporting studies
Strong positive signal

All-cause mortality

Across 1 study, Canagliflozin shows a strong positive signal for All-cause mortality.

1 studies
EvidenceScore™: 56.650000000000006/100
View supporting studies
Strong positive signal

Cardiovascular death

Across 1 study, Canagliflozin shows a strong positive signal for Cardiovascular death.

1 studies
EvidenceScore™: 56.650000000000006/100
View supporting studies
Strong positive signal

Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Across 1 study, Canagliflozin shows a strong positive signal for Composite cardiovascular events (CV death, MI, stroke, HF hospitalization).

1 studies
EvidenceScore™: 56.650000000000006/100
View supporting studies

Studies evaluating SGLT2 Inhibitors

Studies connected to this intervention in the evidence record.

Click outcomes and interventions to filter the archive when links are available.

Related Evidence Topics

Explore related evidence areas connected by shared studies, interventions, or outcomes.

Diabetic Kidney Disease

Mixed

Related because they study similar interventions

5 shared studies

Explore all SGLT2 Inhibitors evidence

Browse the complete evidence archive for this topic, including interventions, outcomes, and related research.

Explore all SGLT2 Inhibitors evidence

Filter by study type, publication date, effect size, and more to refine your research